BOYNTON BEACH, Fla.--(BUSINESS WIRE)--Feb. 6, 2006--Nutra Pharma Corp. (OTCBB:NPHC), a biotechnology company that owns rights to intellectual property related to the development of drugs for HIV and Multiple Sclerosis, has announced that it has engaged Robert A Ollar, PhD to act as the Chairman of Designer Diagnostics' Scientific Advisory Board. Designer Diagnostics is the Company's new wholly-owned subsidiary created for the purpose of marketing diagnostic test kits designed for the rapid isolation and identification of infectious diseases such as Tuberculosis (TB) and Mycobacterium avium-intracellulare (MAI). Nutra Pharma acquired the rights to these diagnostic test kits in a definitive agreement signed with NanoLogix, Inc. (PinkSheets:NNLX).
